We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

88 hedge funds and large institutions have $146M invested in Ovid Therapeutics in 2021 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more capital invested

Capital invested by funds: $64.5M → $146M (+$81.2M)

38% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 16

18% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 22

11.63% more ownership

Funds ownership: 43.51% → 55.14% (+12%)

6% more funds holding

Funds holding: 83 → 88 (+5)

69% less call options, than puts

Call options by funds: $1.25M | Put options by funds: $4.02M

Holders
88
Holders Change
+5
Holders Change %
+6.02%
% of All Funds
1.54%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
22
Increased
26
Reduced
22
Closed
16
Calls
$1.25M
Puts
$4.02M
Net Calls
-$2.77M
Net Calls Change
-$2.27M

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$20.2M
2
SCM
Stonepine Capital Management
Oregon
+$8.25M
3
BI
BVF Inc
California
+$6.3M
4
IC
Ikarian Capital
Texas
+$3.74M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$2.03M

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$3.35M
2
VC
Vivo Capital
California
-$2.89M
3
BBA
Baker Bros. Advisors
New York
-$2.21M
4
CA
CHI Advisors
New York
-$1.93M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$25.8M +$6.3M +1,895,500 +42%
EC
2
EcoR1 Capital
California
$24.4M +$20.2M +6,082,200 New
BlackRock
3
BlackRock
New York
$14.9M +$963K +289,955 +8%
Vanguard Group
4
Vanguard Group
Pennsylvania
$14.1M +$1.3M +390,634 +13%
AG
5
Artal Group
Luxembourg
$10.1M – – –
SCM
6
Stonepine Capital Management
Oregon
$9.98M +$8.25M +2,483,059 New
State Street
7
State Street
Massachusetts
$4.84M +$1.54M +464,925 +63%
IC
8
Ikarian Capital
Texas
$4.52M +$3.74M +1,124,872 New
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$3.87M +$2.03M +609,818 +173%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$3.07M +$638K +192,103 +34%
Goldman Sachs
11
Goldman Sachs
New York
$3.02M +$920K +277,020 +58%
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$2.35M +$1.24M +373,312 +176%
Northern Trust
13
Northern Trust
Illinois
$1.94M -$64.4K -19,386 -4%
Wells Fargo
14
Wells Fargo
California
$1.84M -$310K -93,474 -17%
PIM
15
Platinum Investment Management
Australia
$1.59M – – –
TCM
16
Tekla Capital Management
Massachusetts
$1.5M – – –
Two Sigma Advisers
17
Two Sigma Advisers
New York
$1.28M -$909K -273,800 -46%
Connor, Clark & Lunn Investment Management (CC&L)
18
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.01M +$65.4K +19,705 +8%
CA
19
CHI Advisors
New York
$995K -$1.93M -579,750 -70%
BCM
20
Bridgeway Capital Management
Texas
$922K +$762K +229,400 New
Jacobs Levy Equity Management
21
Jacobs Levy Equity Management
New Jersey
$886K +$606K +182,514 +482%
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$750K +$77.9K +23,444 +14%
N
23
Nuveen
North Carolina
$683K -$18.4K -5,553 -3%
Group One Trading
24
Group One Trading
Illinois
$669K +$335K +100,721 +153%
William Blair & Company
25
William Blair & Company
Illinois
$629K +$62.5K +18,822 +14%
1
2 3 4 5

OVID Hedge Fund Activity: Q1 2021 in Review

88 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2021, worth a combined $146M — up 126% from $64.5M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new OVID positions and 16 closed out — a net gain of 6 holders — while 26 added to existing stakes and 22 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $20.2M. The largest seller was UBS Group, cutting an estimated $3.35M.

  • 88 institutional investors held Ovid Therapeutics (OVID) as of Q1 2021, up from 83 in Q4 2020.
  • Funds reported $146M of Ovid Therapeutics stock for Q1 2021, up 126% quarter-over-quarter.
  • 22 funds opened new Ovid Therapeutics positions in Q1 2021 and 16 closed out, a net change of +6 holders.
  • The largest Ovid Therapeutics buyer in Q1 2021 was EcoR1 Capital, an estimated $20.2M added.
  • The largest Ovid Therapeutics seller in Q1 2021 was UBS Group, an estimated $3.35M sold.

Based on aggregated 13F filings for Q1 2021.